SCHEMBL23979654

SCHEMBL23979654

CSc1nc2c(c(N3CCN(C(=O)OC(C)(C)C)CC3)n1)CCCN2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 2/20 0.39
CHRM3 P20309 2/20 0.38
PDE4A P27815 2/20 0.38
PDE4B Q07343 2/20 0.38
PDE4C Q08493 2/20 0.38
PDE4D Q08499 2/20 0.38
CXCR2 P25025 1/20 0.38
CCNA2 P20248 1/20 0.37
CDK2 P24941 1/20 0.37
KIT P10721 2/20 0.37
GRIA1 P42261 1/20 0.36
DDB1 Q16531 1/20 0.36
CRBN Q96SW2 1/20 0.36
PDE10A Q9Y233 1/20 0.36
CKS1B P61024 2/20 0.36
SKP1 P63208 2/20 0.36
SKP2 Q13309 2/20 0.36
TLR9 Q9NR96 1/20 0.36
SPR P35270 1/20 0.35
OPRM1 P35372 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23979677 0.94 CXCR2 (0.39) GBA1CXCR2CCNA2CDK2KIT
SCHEMBL8340940 0.85 GBA1 (0.41) GBA1CHRM3PDE4APDE4BPDE4C
SCHEMBL21722183 0.83 GBA1 (0.44) GBA1CXCR2CCNA2CDK2CKS1B
SCHEMBL2796064 0.80 KIT (0.49) GBA1KITGRIA1CKS1BSKP1
SCHEMBL19949022 0.79 CCNA2 (0.41) GBA1CXCR2CCNA2CDK2KIT
SCHEMBL25771136 0.75 CXCR2 (0.38) GBA1CXCR2CCNA2CDK2KIT
SCHEMBL30177806 0.74 CCNA2 (0.39) GBA1CXCR2CCNA2CDK2KIT
SCHEMBL21722244 0.74 CCNA2 (0.39) GBA1CXCR2CCNA2CDK2KIT
SCHEMBL21935475 0.74 DDB1 (0.44) KITDDB1CRBNCKS1BSKP1
SCHEMBL23979710 0.72 CHRNA7 (0.41) GBA1CXCR2CCNA2CDK2KIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021219072-A1 PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUND AS KRAS INHIBITOR 上海科州药物研发有限公司 (CN) 2021-11-04 WO disclosed